Company Overview - Yino Pharma plans to globally offer 36.5564 million H-shares, with 3.6558 million shares available in Hong Kong and 32.9006 million shares for international offering [1] - The subscription period is from August 7 to August 12, 2025, with an offering price of HKD 18.68 per share [1] - CICC and CITIC Securities serve as joint sponsors, and shares are expected to start trading on the Hong Kong Stock Exchange on August 15, 2025 [1] Product and Market Focus - Yino Pharma specializes in the research and development of candidate drugs for diabetes and other metabolic diseases [1] - The core product, Isu-Paglutide α, was approved in China in January 2025 for the treatment of type 2 diabetes and began commercialization in February 2025 [1] - This drug is the first domestically approved human-derived long-acting GLP-1 receptor agonist in China, which can be used as monotherapy or in combination with Metformin [1] Market Potential - The GLP-1 therapy market has significant growth potential, with the global market expected to increase from USD 14.7 billion in 2024 to USD 33.8 billion by 2028 [1] - The Chinese market is projected to grow even faster, from RMB 400 million in 2024 to RMB 20.7 billion by 2028 [1]
银诺医药-B招股 预计8月15日挂牌
Zheng Quan Shi Bao Wang·2025-08-07 00:11